ROIV

Roivant Sciences Ltd.

Healthcare
Biotechnology
$29.49B market cap

Forecast run · Sep 15, 2026Upside rank 1626 of 3,136

Model Signal

ForecastQ Daily Probabilities

32.9%

31.8%

18.1%

Analyst Consensus

Recommendation2.07/5 Buy

Last price$40.82

Price target$46.14

Implied move+13.0%

Analysts15

ForecastQ Portfolios

ROIV is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.